Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:38 PM
Ignite Modification Date:
2025-12-24 @ 3:38 PM
NCT ID:
NCT00502892
Eligibility Criteria:
Inclusion Criteria:
1. Age \</= 45years.
2. Histologic proof of solid tumor malignancy (excluding brain stem tumors) at initial diagnosis. Diagnostic Categories include: a) Sarcoma (Soft Tissue and Bone), b) Kidney Tumors, c) Brain Tumors, d) Neuroblastoma, e) Hodgkin's disease and non-Hodgkin's lymphoma, f) Other solid tumors (gonadal and germ cell tumors, malignant melanoma, retinoblastoma, liver tumors, and miscellaneous tumors)
3. If previously treated, must have radiographic, nuclear image, or biopsy proof that they have had a recurrence of their disease within 4 weeks prior to study entry.
4. Performance Level: Karnofsky \>/= 70% for patients \>10 years of age and Lansky Play-Performance Scale \>/=70 for children \</= 10 years of age. Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 2 weeks prior to study entry. Patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score.
5. Life Expectancy \>/= 8 weeks.
6. Full recovery from acute toxic effects of all prior chemo, immuno or XRT: a. No myelosuppressive chemotherapy \</=2 weeks (4 weeks if prior nitrosourea). b. At least 7 days since completion of therapy with biologic agent (anti-neoplastic agent). c. No cranial-spinal \&/or spinal (\>3600 cGy) XRT. No XRT (including TBI) to \> 50% of bone marrow space. d. No evidence of active GVHD. For allogeneic Stem Cell Transplant (SCT), \>/= 6 months must have elapsed. e. Has NOT received exact combination \& dosage of Topotecan, Carboplatin, \& Ifosfamide, as this study recommends, within last 3 months.
7. Adequate Bone Marrow Function: ANC \>/=1000/ micro L; Platelets \>/= 50,000/ micro L (transfusion independent); Hgb \>/= 8.0 gm/dL (may receive RBC transfusions).
8. Adequate Renal function: Serum creatinine \</= 1.5 x normal for age, or Creatinine clearance or radioisotope GFR \>/= lower limit of normal for age.
9. Adequate Liver function: Total bilirubin \</=1.5 x normal for age, and SGPT (ALT) \</= 5 x normal for age and albumin \>/=2 g/dL.
10. Adequate Cardiac Function: Shortening fraction of \>/= 27% by echocardiogram, or Ejection fraction of \>/= 50% by gated radionuclide study.
11. Adequate Pulmonary Function: No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% if there is clinical indication for determination.
12. Central Nervous System Function: Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled. CNS toxicity \< Grade 2.
13. Signed Informed Consent.
Exclusion Criteria:
1. Pregnancy or Breast Feeding.
2. Prior therapy with this particular topotecan, ifosfamide, carboplatin regimen in last 3 months.
3. Patients with bone marrow solid tumor involvement.
4. Patients having received cranial-spinal and or spinal irradiation (\>3600 cGy). Patients who have received radiation therapy (including TBI) to greater than 50% of the bone marrow space.
5. Patients with evidence of active graft vs. host disease and/or patients wiht allogeneic Stem Cell Transplant \[SCT\], \< 6 months.
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
45 Years
Study:
NCT00502892
Study Brief:
Protocol Section:
NCT00502892